Literature DB >> 10191205

Prevalence and changes in hepatitis C virus genotypes among multitransfused persons with hemophilia. The Multicenter Hemophilia Cohort Study.

M E Eyster1, K E Sherman, J J Goedert, A Katsoulidou, A Hatzakis.   

Abstract

The purpose of this study was to determine hepatitis C virus (HCV) genotypes and their relationship to HCV RNA levels over time in a cohort of multitransfused hemophiliacs. Following reverse transcription and polymerase chain reaction amplification of HCV RNA, the product DNAs were genotyped by using the line probe assay. HCV RNA was quantified by the branched-chain DNA assay. Genotyping was done on 109 serum samples from 32 subjects. Genotype 3a had the highest prevalence (41%), followed by genotypes 1a (31%) and 1b (13%). Changes in genotypes were observed in 18 (58%) of the subjects >3-15 years of age. Changes were more common in human immunodeficiency virus (HIV)-positive subjects (13/17) than in HIV-negative subjects (5/15) (P=.014). HCV RNA increased 30-fold in HIV-positive subjects whose genotypes changed. Consensus nucleotide sequencing confirmed genotype changes in 2 patients. We conclude that genotype changes are common in hemophiliacs with chronic HCV, particularly in those who are coinfected with HIV.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10191205     DOI: 10.1086/314708

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  20 in total

1.  Correlates of high hepatitis C virus RNA load in a cohort of HIV-negative and HIV-positive individuals with haemophilia.

Authors:  S M Gadalla; L R Preiss; M E Eyster; J J Goedert
Journal:  J Viral Hepat       Date:  2011-03       Impact factor: 3.728

2.  Knowledge, attitudes, and behaviors of youths in the US hemophilia population: results of a national survey.

Authors:  Ann-Marie Nazzaro; Sally Owens; W Keith Hoots; Kelly L Larson
Journal:  Am J Public Health       Date:  2006-07-27       Impact factor: 9.308

3.  Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network.

Authors:  Robert S Brown; Jacqueline G O'Leary; K Rajender Reddy; Alexander Kuo; Giuseppe J Morelli; James R Burton; R Todd Stravitz; Christine Durand; Adrian M Di Bisceglie; Paul Kwo; Catherine T Frenette; Thomas G Stewart; David R Nelson; Michael W Fried; Norah A Terrault
Journal:  Liver Transpl       Date:  2016-01       Impact factor: 5.799

4.  Genomic and phylogenetic analysis of hepatitis C virus isolates from argentine patients: a six-year retrospective study.

Authors:  J F Quarleri; B H Robertson; V L Mathet; M Feld; L Espínola; M P Requeijo; O Mandó; G Carballal; J R Oubiña
Journal:  J Clin Microbiol       Date:  2000-12       Impact factor: 5.948

Review 5.  Mixed HCV infection and reinfection in people who inject drugs--impact on therapy.

Authors:  Evan B Cunningham; Tanya L Applegate; Andrew R Lloyd; Gregory J Dore; Jason Grebely
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-03-17       Impact factor: 46.802

6.  Comparison and application of a novel genotyping method, semiautomated primer-specific and mispair extension analysis, and four other genotyping assays for detection of hepatitis C virus mixed-genotype infections.

Authors:  Y W Hu; E Balaskas; M Furione; P H Yen; G Kessler; V Scalia; L Chui; G Sher
Journal:  J Clin Microbiol       Date:  2000-08       Impact factor: 5.948

7.  Evaluation of a new assay in comparison with reverse hybridization and sequencing methods for hepatitis C virus genotyping targeting both 5' noncoding and nonstructural 5b genomic regions.

Authors:  Elisa Martró; Victoria González; Andrew J Buckton; Verónica Saludes; Gema Fernández; Lurdes Matas; Ramón Planas; Vicenç Ausina
Journal:  J Clin Microbiol       Date:  2007-11-07       Impact factor: 5.948

8.  Evidence for lack of cross-genotype protection of CD4+ T cell responses during chronic hepatitis C virus infection.

Authors:  G C Harcourt; M Lucas; A J Godkin; M Kantzanou; R E Phillips; P Klenerman
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

9.  Viral dynamic modelling of Hepatitis C and resistance-associated variants in haemophiliacs.

Authors:  K E Sherman; R Ke; S D Rouster; E A Abdel-Hameed; C Park; J Palascak; A S Perelson
Journal:  Haemophilia       Date:  2016-03-03       Impact factor: 4.287

10.  Hepatitis C virus quasispecies in HIV-infected women: role of injecting drug use and highly active antiretroviral therapy (HAART).

Authors:  Tomasz Laskus; Jeffrey Wilkinson; Roksana Karim; Wendy Mack; Marek Radkowski; Marina deGiacomo; Jonathan Nasseri; Zhi Chen; Jiaao Xu; Andrea Kovacs
Journal:  Hepatology       Date:  2007-08       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.